Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:NXTC NASDAQ:TCRT NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.56-4.2%$4.78$3.91▼$7.35$8.76M1.1227,413 shs10,986 shsNXTCNextCure$2.95-7.5%$9.35$2.83▼$15.74$10.66M1.397,821 shs106,909 shsTCRTAlaunos Therapeutics$2.28-6.6%$2.72$1.67▼$6.20$55.68M-1.0717,707 shs42,591 shsUNCYUnicycive Therapeutics$6.92-6.9%$7.32$3.71▼$11.00$184.76M1.73658,050 shs1.19 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-4.20%-13.14%-0.65%+6.05%-29.59%NXTCNextCure-7.52%-52.42%-72.48%-76.19%-48.04%TCRTAlaunos Therapeutics-6.56%-20.00%-13.31%-36.84%-15.24%UNCYUnicycive Therapeutics-6.86%-6.23%-14.88%+5.01%-10.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.56-4.2%$4.78$3.91▼$7.35$8.76M1.1227,413 shs10,986 shsNXTCNextCure$2.95-7.5%$9.35$2.83▼$15.74$10.66M1.397,821 shs106,909 shsTCRTAlaunos Therapeutics$2.28-6.6%$2.72$1.67▼$6.20$55.68M-1.0717,707 shs42,591 shsUNCYUnicycive Therapeutics$6.92-6.9%$7.32$3.71▼$11.00$184.76M1.73658,050 shs1.19 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-4.20%-13.14%-0.65%+6.05%-29.59%NXTCNextCure-7.52%-52.42%-72.48%-76.19%-48.04%TCRTAlaunos Therapeutics-6.56%-20.00%-13.31%-36.84%-15.24%UNCYUnicycive Therapeutics-6.86%-6.23%-14.88%+5.01%-10.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.40Hold$34.67660.23% UpsideNXTCNextCure 2.20Hold$23.00679.66% UpsideTCRTAlaunos Therapeutics 1.00SellN/AN/AUNCYUnicycive Therapeutics 2.67Moderate Buy$24.75257.66% UpsideCurrent Analyst Ratings BreakdownLatest TCRT, NXTC, UNCY, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSpeculative Buy$15.00 ➝ $18.005/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026BOLTBolt Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/28/2026BOLTBolt Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/27/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/15/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026UNCYUnicycive Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $37.005/6/2026NXTCNextCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026NXTCNextCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.70M1.14N/AN/A$13.81 per share0.33NXTCNextCureN/AN/AN/AN/A$9.97 per shareN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/A$0.93 per shareN/AUNCYUnicycive Therapeutics$680K271.71N/AN/A$1.41 per share4.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$33.38M-$16.33N/AN/AN/A-455.15%-100.89%-48.23%8/13/2026 (Estimated)NXTCNextCure-$55.84M-$17.19N/AN/AN/AN/A-186.96%-124.62%8/6/2026 (Estimated)TCRTAlaunos Therapeutics-$4.18M-$2.13N/AN/AN/AN/A-165.94%-123.50%8/18/2026 (Estimated)UNCYUnicycive Therapeutics-$26.56M-$2.21N/A0.85N/AN/A-134.69%-84.51%8/13/2026 (Estimated)Latest TCRT, NXTC, UNCY, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026TCRTAlaunos TherapeuticsN/A-$0.59N/A-$0.59N/AN/A5/12/2026Q1 2026BOLTBolt Biotherapeutics-$2.85-$4.31-$1.46-$4.31$1.50 million$0.03 million5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A5/7/2026Q1 2026NXTCNextCure-$2.1050-$1.87+$0.2350-$1.87N/AN/A3/31/2026Q4 2025TCRTAlaunos TherapeuticsN/A-$0.36N/A-$0.36N/A$0.00 million3/30/2026Q4 2025UNCYUnicycive Therapeutics-$0.46-$0.82-$0.36-$0.82$0.52 millionN/A3/12/2026Q4 2025BOLTBolt Biotherapeutics-$4.27-$3.84+$0.43-$3.84$0.67 million$2.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.983.513.51NXTCNextCureN/A4.614.61TCRTAlaunos TherapeuticsN/A1.631.63UNCYUnicycive TherapeuticsN/A2.402.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%NXTCNextCure42.65%TCRTAlaunos Therapeutics27.72%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics9.40%NXTCNextCure11.90%TCRTAlaunos Therapeutics16.14%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.74 millionNot OptionableNXTCNextCure903.61 million3.18 millionNo DataTCRTAlaunos Therapeutics4024.42 million20.48 millionNo DataUNCYUnicycive Therapeutics926.70 million23.84 millionNot OptionableTCRT, NXTC, UNCY, and BOLT HeadlinesRecent News About These CompaniesUnicycive Expands At-The-Market Equity Offering ProgramJune 5 at 5:50 PM | tipranks.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)June 5 at 7:29 AM | theglobeandmail.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Rating of "Moderate Buy" from BrokeragesMay 30, 2026 | americanbankingnews.comUnicycive Therapeutics: A Catalyst Play With Real Fundamental UpsideMay 21, 2026 | seekingalpha.comUnicycive Therapeutics Inc Ordinary Shares UNCYMay 16, 2026 | morningstar.comMUnicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20May 14, 2026 | msn.comUnicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?May 14, 2026 | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | finanznachrichten.deUnicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch PreparationsMay 12, 2026 | quiverquant.comQUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comUnicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 16, 2026 | seekingalpha.comUnicycive Therapeutics Inc.April 11, 2026 | barrons.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmApril 9, 2026 | prnewswire.comUnicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comPiper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)April 2, 2026 | theglobeandmail.comUNCY retail buzz explodes 150% this week as traders bet big on experimental drug approvalApril 1, 2026 | msn.comUnicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmMarch 6, 2026 | newsfilecorp.comNImportant Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your BehalfFebruary 17, 2026 | newsfilecorp.comNUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech SummitFebruary 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Marvell’s Pullback May Be the Setup Bulls Were Waiting ForBy Thomas Hughes | May 29, 2026Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNowBy Thomas Hughes | June 3, 2026TCRT, NXTC, UNCY, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$4.56 -0.20 (-4.20%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.70 +0.15 (+3.18%) As of 06/5/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.NextCure NASDAQ:NXTC$2.95 -0.24 (-7.52%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.92 -0.03 (-1.15%) As of 06/5/2026 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Alaunos Therapeutics NASDAQ:TCRT$2.28 -0.16 (-6.56%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.37 +0.09 (+3.95%) As of 06/5/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Unicycive Therapeutics NASDAQ:UNCY$6.92 -0.51 (-6.86%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$7.04 +0.12 (+1.79%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
